M&A / Merger2026-06-25

TKG Huchems acquires 10.8% stake in Aprilbio

TKG

티케이지휴켐스

069260

+0.05

Signal Score

50CNeutral
Score50 / 100

Historical Avg Return (5d)

+0.00%

Data Coverage

100%n=616

Risk-adjusted indicator based on 616 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • Acquisition Amount: 149,999,994,117 KRW
  • • Stake Acquired: 10.8% (3,492,189 Shares)
  • • Acquisition Ratio to Equity: 16.5%
  • • Aprilbio Current Year Net Income: -9,728,011,089 KRW (2025)
  • • Aprilbio Previous Year Net Income: 20,005,162,287 KRW (2024)

AI Analysis Summary

TKG Huchems Co.,Ltd. has decided to acquire 3,492,189 shares (10.8% stake) of Aprilbio Co., Ltd. for 149,999,994,117 KRW, representing 16.5% of TKG Huchems' equity. The acquisition, through a third-party allocation paid-in capital increase, aims for business diversification. The transaction includes call/put options and co-sale rights, indicating a strategic, long-term investment rather than immediate control. Aprilbio reported a net loss of 9.73B KRW in 2025, a decline from a 20.01B KRW net profit in 2024. The acquisition is a joint investment with IMM Asset Management and IMM Scale-up Bio No. 1.

Track Korean Market Signals — Free

Sign up free to access live disclosures, AI analysis, and event filters.

Public Beta · No credit card required

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: 타법인주식및출자증권취득결정 . Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.